Proteins are the building blocks of the human body and have many critical roles. Since proteins are involved in multiple biological functions, they also play an important role in diseases. By understanding proteins better, biomedical researchers can develop new drugs. However, this requires knowing the proteome or the complete set of proteins expressed by a living being. Until recently, studying the proteome was extremely challenging.

Nautilus Biotechnology, a life sciences company that is unlocking the complexity of the proteome, announced its debut as a publicly traded company on NASDAQ

NDAQ
under the ticker symbol NAUT. The company went public via the special acquisitions company (SPAC), Arya III. Nautilus plans to continue to work on proteome technology that will create…

Read more…

Share.

Comments are closed.